Cable Hill Partners LLC Has $565,000 Holdings in Moderna, Inc. (NASDAQ:MRNA)

Cable Hill Partners LLC cut its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 8.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,406 shares of the company’s stock after selling 216 shares during the quarter. Cable Hill Partners LLC’s holdings in Moderna were worth $565,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of MRNA. Acadian Asset Management LLC increased its position in shares of Moderna by 78.6% during the first quarter. Acadian Asset Management LLC now owns 7,894 shares of the company’s stock worth $1,033,000 after buying an additional 3,475 shares during the period. Sei Investments Co. increased its position in shares of Moderna by 5.2% during the first quarter. Sei Investments Co. now owns 54,703 shares of the company’s stock worth $6,980,000 after buying an additional 2,723 shares during the period. E Fund Management Co. Ltd. acquired a new stake in shares of Moderna during the first quarter worth $661,000. Quilter Plc increased its position in shares of Moderna by 156.7% during the first quarter. Quilter Plc now owns 15,518 shares of the company’s stock worth $2,032,000 after buying an additional 9,473 shares during the period. Finally, Quadrant Capital Group LLC increased its position in shares of Moderna by 27.5% during the first quarter. Quadrant Capital Group LLC now owns 1,336 shares of the company’s stock worth $175,000 after buying an additional 288 shares during the period. Institutional investors own 55.89% of the company’s stock.

In related news, President Stephen Hoge sold 20,000 shares of the stock in a transaction dated Monday, September 13th. The shares were sold at an average price of $447.41, for a total transaction of $8,948,200.00. Following the sale, the president now directly owns 1,614,597 shares of the company’s stock, valued at approximately $722,386,843.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Juan Andres sold 5,000 shares of the company’s stock in a transaction dated Friday, July 16th. The shares were sold at an average price of $276.51, for a total transaction of $1,382,550.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 349,000 shares of company stock valued at $133,921,880. Company insiders own 19.40% of the company’s stock.

Shares of MRNA traded up $9.07 during mid-day trading on Thursday, reaching $330.57. The company’s stock had a trading volume of 208,422 shares, compared to its average volume of 14,438,114. The stock has a market cap of $133.43 billion, a PE ratio of 40.09, a P/E/G ratio of 0.37 and a beta of 1.50. The company has a current ratio of 1.24, a quick ratio of 1.17 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52 week low of $65.49 and a 52 week high of $497.49. The company’s fifty day moving average price is $394.73 and its two-hundred day moving average price is $273.13.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 5th. The company reported $6.46 earnings per share for the quarter, topping the Zacks’ consensus estimate of $6.01 by $0.45. The firm had revenue of $4.35 billion during the quarter, compared to analyst estimates of $4.23 billion. Moderna had a net margin of 49.79% and a return on equity of 88.13%. The business’s quarterly revenue was up 6457.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.31) EPS. Research analysts anticipate that Moderna, Inc. will post 29.13 EPS for the current year.

A number of equities research analysts have commented on the stock. Chardan Capital restated a “buy” rating on shares of Moderna in a report on Wednesday, July 7th. Argus raised their price objective on shares of Moderna from $200.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, June 24th. Piper Sandler lowered shares of Moderna from an “overweight” rating to a “neutral” rating in a research report on Friday, August 6th. Zacks Investment Research lowered shares of Moderna from a “buy” rating to a “hold” rating and set a $330.00 price target on the stock. in a research report on Monday, July 19th. Finally, Oppenheimer lowered shares of Moderna from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 5th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $205.21.

Moderna Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Story: Correction

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.